An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. (Q51874162)

15 April 2018

title

An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. (English)

1 reference

15 April 2018

author name string

John F Hewetson

1

1 reference

15 April 2018

Stephen F Little

2

1 reference

15 April 2018

Bruce E Ivins

3

1 reference

15 April 2018

Wendy M Johnson

4

1 reference

15 April 2018

Phillip R Pittman

5

1 reference

15 April 2018

J Edward Brown

6

1 reference

15 April 2018

Sarah L Norris

7

1 reference

15 April 2018

Carl J Nielsen

8

1 reference

15 April 2018

language of work or name

English

0 references

publication date

12 June 2008

1 reference

15 April 2018

published in

Vaccine

1 reference

15 April 2018

volume

26

1 reference

15 April 2018

issue

33

1 reference

15 April 2018

page(s)

4262-4266

1 reference

15 April 2018

Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

In vitro correlate of immunity in a rabbit model of inhalational anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Postexposure prophylaxis against experimental inhalation anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

In vitro correlate of immunity in an animal model of inhalational anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Search for correlates of protective immunity conferred by anthrax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Antigen delivery by attenuated Bacillus anthracis: new prospects in veterinary vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Passive transfer of protection against Bacillus anthracis infection in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Murine aerosol challenge model of anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Validation of the anthrax lethal toxin neutralization assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

A good practice guide to the administration of substances and removal of blood, including routes and volumes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.068

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.05.068

1 reference

15 April 2018

PubMed ID

18586363

1 reference

15 April 2018